The Medical Letter on Drugs and Therapeutics
Idarucizumab (Praxbind) - An Antidote for Dabigatran
November 23, 2015 (Issue: 1482)The FDA has approved idarucizumab (Praxbind – Boehringer Ingelheim) for urgent reversal of the anticoagulant effect of the direct thrombin inhibitor dabigatran etexilate (Pradaxa). Idarucizumab is the first specific reversal agent to become...more
- Dabigatran etexilate (Pradaxa) — a new oral anticoagulant. Med Lett Drugs Ther 2010; 52:89.
- Edoxaban (Savaysa) – the fourth new oral anticoagulant. Med Lett Drugs Ther 2015; 57:43.
- Bleeding with dabigatran (Pradaxa). Med Lett Drugs Ther 2011; 53:98.
- CV Pollack Jr et al. Idarucizumab for dabigatran reversal. N Engl J Med 2015; 373:511.
- S Glund et al. Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet 2015; 386:680.
- S Glund. A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran. Thromb Haemost 2015; 113:943.
- Approximate wholesale acquisition cost (WAC). WAC = wholesaler acquisition cost or manufacturer’s published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price. Source: AnalySource® Monthly. November 5, 2015. Reprinted with permission by First Databank, Inc. All rights reserved. ©2015. www.fdbhealth.com/policies/drug-pricing-policy.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.